---
created: 2026-05-10
status: archived-originals
source: ascvd-lpa-prevention-slimming
---

# ASCVD / Lp(a) Prevention Cluster Original Text Archive — 2026-05-10

This archive preserves the full pre-consolidation text of the overlapping ASCVD/Lp(a) prevention pages before the active KB was slimmed. The active report should use `lp-a.md` as the canonical ASCVD / Lp(a) Prevention Master; this file is provenance/recovery, not active guidance.


---

## Original `lp-a.md`

```markdown
---
topic: Lipoprotein(a) - Lp(a)
tags: [cardiovascular, lipids, genetics, risk-factor]
priority: urgent
last_updated: 2026-04-29
confidence: high
abstract: >-
  Lp(a) 838.6 mg/L is the fixed genetic cardiovascular risk anchor. This page owns the stable
  interpretation and decision map: preserve the raw unit, treat standard calculators as
  underestimates, control ApoB/LDL, smoking and BP aggressively, image disease burden/valves,
  avoid primary-prevention aspirin while bleeding risk is live, and monitor outcomes-proven
  Lp(a)-specific therapies elsewhere.
open_questions:
  - Should PCSK9 inhibitor be pursued now as a bridge, or mainly after imaging clarifies plaque burden?
  - Can future retesting obtain an nmol/L assay rather than relying on rough mg/L conversion?
  - What imaging pathway is most practical locally if CAC/CCTA/echo becomes the next cardiovascular step?
---

# Lipoprotein(a) - Lp(a)

## Summary

Lp(a) is the stable cardiovascular anchor in this KB. The measured value is **838.6 mg/L** (reference <250 mg/L), roughly **83.9 mg/dL** by simple division but not reliably convertible to nmol/L because apo(a) isoform size and assay method matter.

The action is not “lower Lp(a) with lifestyle.” Lp(a) is mostly genetic. The current management sequence is:

1. Preserve the raw value/unit and repeat in nmol/L if available.
2. Control every modifiable risk driver harder than a standard calculator would suggest.
3. Keep ApoB/LDL low; consider PCSK9 as a bridge depending on plaque burden, targets, cost, and specialist input.
4. Measure actual disease burden with cardiovascular imaging and valve baseline.
5. Keep aspirin off the table for primary prevention while GI bleeding risk is unresolved.
6. Track Lp(a)-specific drug outcomes and access in the watchlist, not here.

## What this page owns

| Topic | This anchor owns | Delegated page |
|---|---|---|
| Baseline Lp(a) interpretation | Raw value, unit caution, causal risk role | — |
| Prevention status | High-risk primary prevention until disease burden is documented | [Prevention Status + CVD Burden](#sec-prevention-status) |
| Imaging | Why imaging matters; not the full scan algorithm | [Aortic Valve + Vascular Aging](#sec-aortic-valve-vascular-aging), [LDNCP Imaging for Lp(a)](#sec-ldncp-imaging), [CT Scan Preventive Screening](#sec-ct-scan) |
| PCSK9 / therapy pipeline | Current role in the decision map | [Lp(a) Therapy Watchlist](#sec-lpa-therapy-watchlist) |
| Aspirin / antithrombotics | Boundary rule: no primary-prevention aspirin now | [Antithrombotic Strategy](#sec-antithrombotic) |
| Smoking / alcohol | Smoking is the highest-ROI modifiable amplifier | [Smoking + Alcohol Relapse Risk](#sec-smoking-alcohol-relapse) |
| BP | Missing major risk variable | [Blood Pressure Profile](#sec-blood-pressure) |
| Platelets / thrombosis | Risk modifier, not arithmetic multiplier | [Thrombocytosis Workup](#sec-thrombocytosis) |

## Baseline interpretation

| Point | Interpretation |
|---|---|
| Result | 838.6 mg/L, very high. |
| Unit handling | Store exactly as reported. Use mg/dL only as rough orientation; prefer nmol/L retest if available. |
| Causality | Strongest for ASCVD and calcific aortic valve disease. |
| Thrombosis mechanism | Apo(a)-plasminogen homology and oxidized phospholipids are biologically plausible; clinical VTE/fibrinolysis claims are less settled than ASCVD/CAVS. |
| Standard calculators | Likely underestimate risk because Lp(a) is not directly modeled. |

Guideline-style thresholds commonly treat Lp(a) above about 50 mg/dL or 105-125 nmol/L as a risk-enhancing factor. This value is well above that range. The practical consequence is aggressive management of modifiable risk and earlier disease-burden measurement, not panic arithmetic.

Sources: PMID: 41381044, PMID: 41899103.

## Current risk modifiers

| Modifier | Why it matters |
|---|---|
| Lp(a) 838.6 mg/L | Fixed genetic risk enhancer; cannot be lifestyle-normalized. |
| ApoB 66.31 mg/dL / LDL 2.04 mmol/L on atorvastatin | Reassuring, but does not erase Lp(a) risk. |
| Active/recent smoking | Highest-ROI modifiable risk amplifier: endothelial injury, inflammation, platelet activation, plaque risk. |
| Blood pressure | Major missing variable; should be measured during the clean experiment window. |
| Platelets/WBC/fibrinogen/inflammation | Risk context; do not convert into pseudo-precise multipliers. |
| Diverticular/occult bleeding | Raises the cost of aspirin or casual antithrombotics. |
| CAC/CCTA/echo status | Decides whether risk is only a risk factor or already visible disease burden. |

## Medication strategy

**Statin:** Atorvastatin remains beneficial. Statins may raise Lp(a) modestly in some studies, but LDL/ApoB reduction and plaque-stabilizing benefit outweigh that issue.

**Ezetimibe:** Useful for further LDL-C lowering if needed; not meaningful Lp(a) lowering.

**PCSK9 inhibitors:** Best available bridge option if medication intensification is chosen. They lower LDL/ApoB strongly and Lp(a) modestly (often around 20-30%). At 838.6 mg/L, that would still leave Lp(a) very high, so PCSK9 is best framed as LDL/ApoB intensification with modest Lp(a) help, not as Lp(a) normalization. The decision belongs with plaque burden, LDL/ApoB targets, cost/access, and cardiology review.

**Niacin:** Not recommended for routine cardiovascular prevention. It can lower Lp(a), but outcome trials failed to show enough benefit and side effects are real.

**Emerging therapies:** Pelacarsen, olpasiran, muvalaplin, lepodisiran, zerlasiran and related programs belong in the [Lp(a) Therapy Watchlist](#sec-lpa-therapy-watchlist). Biomarker reductions are now impressive; outcomes, approval, access, and price are the limiting questions.

## Imaging and prevention sequence

The imaging question is not “does Lp(a) exist?” It is “has it already produced plaque or valve disease?”

Current sequence:

1. **Echo baseline** for aortic valve because high Lp(a) is causal for calcific aortic valve stenosis.
2. **CAC** as a low-friction coronary plaque anchor.
3. **CCTA / plaque characterization** if CAC is positive enough, symptoms recur, or non-calcified plaque burden would change management.
4. Use imaging results to decide how aggressively to push LDL/ApoB, PCSK9, BP targets, and specialist follow-up.

Full branch logic lives in [Aortic Valve + Vascular Aging](#sec-aortic-valve-vascular-aging), [Prevention Status + CVD Burden](#sec-prevention-status), and [LDNCP Imaging for Lp(a)](#sec-ldncp-imaging).

## Antithrombotic boundary

High Lp(a) is one reason aspirin keeps resurfacing in the literature, but the current boundary is firm:

- **No primary-prevention aspirin** while diverticular bleeding / occult stool blood risk is live.
- If imaging or events later create a true secondary-prevention indication, antithrombotic decisions become cardiology + GI risk balancing.

Current medication/supplement safety details live in [Medication List + Hard Avoids](#sec-medication-avoid-list); antiplatelet/aspirin tradeoffs live in [Antithrombotic Strategy](#sec-antithrombotic).

## Family screening

Lp(a) is inherited and stable enough that first-degree relatives should be screened once. Brother already appears affected, which supports the genetic framing. Family screening does not change Dag’s immediate management, but it is high-yield for relatives because standard lipid panels can miss the risk.

## Action

1. Keep atorvastatin as the lipid floor unless a clinician changes the plan.
2. During the current clean month, collect BP and smoking/alcohol-free baseline data; BP and smoking are modifiable in a way Lp(a) is not.
3. Discuss echo + CAC/CCTA pathway when logistics allow.
4. Consider PCSK9 as a bridge discussion after plaque burden, LDL/ApoB target, cost/access, and clinician preference are clearer.
5. Do not use aspirin for primary prevention under current GI-bleeding uncertainty.
6. Retest Lp(a) in nmol/L if available; otherwise preserve the original mg/L result exactly.
7. Track therapy outcomes/access in the watchlist rather than expanding this anchor.

```


---

## Original `prevention-status-cvd-burden.md`

```markdown
---
topic: Primary vs Secondary Prevention Status and Actual Cardiovascular Disease Burden
tags: [cardiovascular, prevention-status, lp(a), cac, ccta, aspirin, pcsk9, apob]
priority: urgent
last_updated: 2026-04-27
confidence: medium-high
abstract: >-
  Prevention status should not be guessed from Lp(a) alone. Until imaging or clinical ASCVD is documented,
  this remains high-risk primary prevention with secondary-prevention-style risk-factor intensity, not automatic
  antiplatelet therapy. CAC/CCTA/echo are the boundary tests: plaque or valve disease changes risk tier,
  follow-up intensity, and how strongly to discuss PCSK9-level LDL/ApoB lowering.
related_topics: [lp-a.md, aortic-valve-vascular-aging.md, ldncp-advanced-imaging.md, ct-scan-screening.md, antithrombotic-strategy.md, thrombocytosis-lpa-thrombosis.md]
open_questions: [What does baseline CAC/CCTA/echo show? What LDL/ApoB target will the treating cardiologist use if plaque is present?]
---

# Primary vs Secondary Prevention Status and Actual Cardiovascular Disease Burden

## SearchPlan

- **Question type:** clinical decision synthesis / risk classification.
- **Question:** Does this profile remain primary prevention, or do Lp(a), symptoms, biomarkers, or imaging findings move it into documented ASCVD / secondary-prevention territory?
- **Dag-specific context:** male 51, Lp(a) 838.6 mg/L, ApoB 66.31 mg/dL, LDL 2.04 mmol/L on atorvastatin 20 mg, active/recent smoking, no documented MI/stroke/PAD/revascularization, early-April 2025 epigastric/abdominal pain with autonomic + left-arm/hand symptoms, diverticular hemorrhage history plus current stool-blood uncertainty.
- **Concepts searched:** Lp(a) risk-enhancer guidance; CAC/CCTA plaque burden risk reclassification; chronic coronary disease / secondary-prevention definitions; aspirin primary-prevention limits; LDL/ApoB intensification by risk tier.
- **Target sources:** ACC/AHA primary prevention/chronic coronary disease guidance, ESC chronic coronary syndrome guidance, 2025 ESC/EAS dyslipidaemia focused update, Lp(a)+CAC cohort evidence, existing KB imaging/antithrombotic topics.
- **Stop condition:** enough evidence to define a practical branch table for CAC/CCTA/echo results and update the queue.

## Bottom Line

Current status is **high-risk primary prevention until imaging or clinical events document otherwise**. Lp(a) this high is causal and important, but it is still a risk factor, not proof of clinical ASCVD. The boundary changes when one of these is documented:

- prior MI, angina with objective ischemia, stroke/TIA, PAD, coronary revascularization, or obstructive coronary disease
- CCTA showing coronary plaque/stenosis, especially obstructive or high-risk plaque
- CAC >0 showing subclinical coronary atherosclerosis; higher scores strengthen the treatment-intensity case
- echo showing Lp(a)-linked aortic valve sclerosis/stenosis, which is not ASCVD but does document target-organ disease and changes surveillance

So the practical stance is: **treat modifiable risk factors aggressively now, but do not import every secondary-prevention drug rule until actual disease burden is shown.**

## Decision Framework

| Finding | Prevention-status interpretation | What changes |
|---|---|---|
| No prior ASCVD and no imaging yet | High-risk primary prevention | Continue statin; smoking/BP control; get baseline echo and coronary imaging discussion. No aspirin. |
| CAC = 0 | Still primary prevention; near-term calcified-plaque risk lower, not zero | Continue aggressive risk-factor control. CCTA only if symptoms recur, clinician concern persists, or direct plaque composition is worth the extra contrast/radiation. |
| CAC 1-99 | Subclinical atherosclerosis | Cardiology discussion; tighten LDL/ApoB target discussion; PCSK9/ezetimibe becomes more defensible if target is not met. Aspirin still not casual because GI bleeding risk is real. |
| CAC 100-399 | Meaningful plaque burden | Treat as a much higher-risk prevention state. Cardiology review, tighter LDL/ApoB goal, PCSK9 discussion, and CCTA if anatomy/plaque composition would change management. |
| CAC >=400 | Severe calcified plaque burden | High-risk coronary disease workup; CCTA vs functional testing per cardiology. Medication intensity should be specialist-guided. |
| CCTA: non-obstructive plaque | Documented coronary atherosclerosis, not automatically classic post-MI secondary prevention | Stronger LDL/ApoB lowering case; plaque features decide urgency. Aspirin remains individualized because bleeding risk can outweigh benefit. |
| CCTA: obstructive CAD or ischemia-producing disease | Chronic coronary disease / secondary-prevention-style management | Cardiology-led lipid, antithrombotic, BP, and follow-up plan. GI bleeding history must be part of antiplatelet choice. |
| Echo: aortic sclerosis/stenosis | Lp(a)-linked valve disease documented | Valve surveillance interval; see [Aortic Valve + Vascular Aging](#sec-aortic-valve-vascular-aging). Reinforces seriousness of Lp(a), but does not by itself create an aspirin indication. |

## LDL/ApoB Target Logic

The current ApoB (~66 mg/dL) and LDL-C (~79 mg/dL) are good for ordinary primary prevention, but the target depends on actual disease burden:

- **No plaque documented:** ApoB around 65-80 mg/dL is already close to many aggressive primary-prevention goals; focus shifts heavily to smoking cessation, BP measurement, and imaging.
- **CAC >0 or CCTA plaque:** discuss whether to target roughly **LDL-C <55-70 mg/dL** and ApoB below the current level, depending on cardiologist framework and plaque burden.
- **Obstructive CAD / chronic coronary disease:** use secondary-prevention intensity; non-statin therapy becomes much easier to justify if LDL/ApoB are above the selected target.

PCSK9 inhibitors are best framed as a **bridge option**: modest Lp(a) lowering plus strong LDL/ApoB lowering now. They are not mandatory from Lp(a) alone, but the case gets much stronger if imaging documents plaque or if the treating cardiologist uses very-high-risk LDL/ApoB targets.

## Aspirin / Antithrombotic Boundary

Aspirin remains **off the table for current primary prevention**. ACC discussion of aspirin in elevated Lp(a) is explicitly patient-centered and most plausible when bleeding risk is low. That is not this profile: documented diverticular hemorrhage plus current stool-blood uncertainty creates a real bleeding penalty.

If CCTA or another workup later documents chronic coronary disease, aspirin is no longer a casual yes/no. It becomes a cardiology + GI tradeoff: ischemic risk, plaque anatomy, stool-blood/iron trend, and whether an antiplatelet is truly indicated.

Current medication/supplement safety details live in [Medication List + Hard Avoids](#sec-medication-avoid-list); antiplatelet/aspirin tradeoffs live in [Antithrombotic Strategy](#sec-antithrombotic).

## Imaging Sequence That Answers the Queue Item

1. **Baseline echocardiogram** for aortic valve and LV function. This answers the Lp(a)-valve question that CAC cannot.
2. **CAC** if asymptomatic and low-friction risk anchoring is the goal.
3. **CCTA with plaque characterization** if symptoms recur, CAC is positive enough to change management, or the goal is to directly answer non-calcified plaque burden rather than stage through CAC.
4. **Immediate ECG + high-sensitivity troponin / ER pathway** if the early-April 2025 symptom cluster recurs. That scenario is not screening; it is rule-out-ACS logistics.

## Evidence Layer

**Guidelines / statements**
- 2019 ACC/AHA primary prevention guidance de-emphasizes routine aspirin; aspirin is only a selective option for adults 40-70 at elevated ASCVD risk without increased bleeding risk (PMID: 30879355).
- 2023 AHA/ACC chronic coronary disease guideline defines the management domain once coronary disease is documented and supports secondary-prevention-style medical therapy in established CCD (PMID: 37471501).
- 2024 ESC chronic coronary syndrome guideline treats CCTA/functional testing as diagnostic/risk-stratification tools in suspected chronic coronary disease (PMID: 39210710).
- 2025 ESC/EAS dyslipidaemia focused update further emphasizes earlier, more individualized LDL-C intensification for higher-risk patients (PMID: 41785983).

**Cohort / imaging evidence**
- Multicohort Lp(a)+CAC data support both points at once: elevated Lp(a) predicts higher long-term ASCVD risk, while CAC=0 retains strong negative predictive value; the highest risk is the combination of elevated Lp(a) plus CAC>0. This supports CAC as a risk-stratification anchor, not as a full Lp(a) eraser.
- Existing KB evidence already covers why CCTA matters in this profile: Lp(a) is associated with non-calcified/high-risk plaque features that CAC can miss, while CCTA can show plaque type, stenosis, and high-risk morphology.

## Key Takeaways for This Profile

1. The canonical label today is **high-risk primary prevention**, not established secondary prevention.
2. Lp(a) 838.6 mg/L justifies aggressive risk-factor management, but it does not by itself prove coronary disease or justify aspirin in a high-bleeding-risk patient.
3. Imaging is the divider: CAC/CCTA/echo convert the discussion from risk factors to actual disease burden.
4. CAC=0 would be reassuring but not a reason to relax smoking, ApoB/LDL, BP, or valve surveillance.
5. Any CAC>0 makes the PCSK9 / tighter ApoB conversation more concrete; obstructive/high-risk CCTA makes it cardiology-led secondary-prevention-style management.
6. Aspirin stays avoided unless documented disease creates a true antithrombotic indication and GI bleeding risk is deliberately weighed.

## Research Trace

- **Research date:** 2026-04-27.
- **Sources searched:** existing KB topics (`lp-a.md`, `ldncp-advanced-imaging.md`, `ct-scan-screening.md`, `antithrombotic-strategy.md`), live cloud doc, PubMed, ACC/AHA, ESC, ACC expert analysis.
- **Query summary:** lipoprotein(a) + CAC/CCTA + primary prevention; chronic coronary disease guideline + antiplatelet; ESC chronic coronary syndrome; Lp(a)+aspirin primary prevention; Lp(a)+CAC risk prediction.
- **Evidence anchors:** PMIDs 30879355, 37471501, 39210710, 41785983; ACC 2024 Lp(a)+aspirin expert analysis; multicohort Lp(a)+CAC summaries.
- **Unresolved gaps:** actual CAC/CCTA/echo findings; blood-pressure profile; cardiologist-selected LDL/ApoB target if plaque is present.

```


---

## Original `hdl.md`

```markdown
---
topic: HDL Cholesterol
tags: [lipids, cardiovascular, metabolic-health]
priority: monitor
last_updated: 2026-04-30
confidence: high
abstract: >-
  High HDL does not neutralize Lp(a), smoking, or plaque uncertainty. HDL near the high end is
  mostly context; ApoB/LDL lowering, smoking cessation, imaging, blood pressure, and
  inflammation/bleeding context remain the cardiovascular levers that matter.
open_questions:
  - Should NMR lipoprotein particle analysis be done to check HDL subtype distribution?
  - Was the temporary rise to 2.53 just natural variation, given the latest HDL is 1.99?
  - Are SCARB1 or CETP genetic variants worth testing given this HDL pattern?
---

# HDL Cholesterol

## HDL U-Shaped Mortality Curve

The belief that "higher HDL is always better" has been thoroughly overturned by large-scale epidemiological studies over the past decade. Current evidence demonstrates a J-shaped or U-shaped relationship between HDL-C levels and both all-cause and cardiovascular mortality.

**Key studies (2024-2026):**

- Shaikh et al. (PMID 41618310, Eur J Med Res, Jan 2026): Confirmed very high HDL-C faces increased CV mortality risk compared to moderate levels
- Shi et al. (PMID 41284745, Eur J Prev Cardiol, Nov 2025): Very high HDL-C associated with increased CV mortality risk, particularly above 2.6 mmol/L (~100 mg/dL)
- Ryu et al. (PMID 40443511, Front Med, 2025): Males with extremely high HDL-C had paradoxically elevated all-cause mortality. Inflection point approximately 2.3-2.6 mmol/L
- JAMA Cardiology (PMID 35583863): U-shaped association with nadir at 1.55-1.81 mmol/L, risk increased substantially above 2.07 mmol/L

**Consensus**: Optimal HDL-C is approximately 1.3-2.1 mmol/L (50-80 mg/dL). Above 2.3 mmol/L (~90 mg/dL), mortality curve begins to turn upward. Above 2.6 mmol/L (~100 mg/dL), risk becomes more clearly elevated.

## Very High HDL and Cardiovascular Risk

Current evidence: HDL-C above reference range is not universally protective and, at very high levels, may indicate increased risk. Several mechanisms:

1. **Dysfunctional HDL particles**: At very high concentrations, HDL may undergo structural modifications (oxidation, glycation) rendering them pro-inflammatory rather than anti-inflammatory
2. **CETP deficiency or SCARB1 mutations**: Genetic variants causing very high HDL-C can paradoxically increase cardiovascular risk. SCARB1 loss-of-function impairs hepatic cholesterol uptake from HDL
3. **Saturated cholesterol efflux capacity**: Very high HDL-C may reflect oversaturated system where HDL cannot efficiently take up additional cholesterol from peripheral tissues
4. **Increased oxidative stress**: Some studies suggest very high HDL-C reflects chronic low-grade inflammation where HDL becomes modified and loses protective function

For this profile: HDL has ranged from roughly 2.0 to 2.53 mmol/L, but the newest value is 1.99 mmol/L (77 mg/dL). That matters because it pulls the profile back into a much less concerning range. The prior 2.53 now looks more like a temporary high reading than a sustained march into the U-curve danger zone.

## HDL Function vs Quantity

The distinction between HDL quantity (HDL-C level) and HDL function has become one of the most important paradigm shifts in cardiovascular risk assessment.

- **Zhang et al. (PMID 40858201, Clin Chim Acta, Jan 2026)**: Comprehensive review documenting shift from measuring HDL-C concentration to assessing HDL functionality
- **Cholesterol efflux capacity (CEC)**: Ability of HDL to accept and transport cholesterol from arterial plaques back to liver. Inversely associated with CV events, independent of HDL-C levels
- **Anti-inflammatory capacity**: Healthy HDL suppresses endothelial activation, inhibits LDL oxidation, promotes nitric oxide production
- **Clinical trials of HDL-raising drugs**: Niacin, CETP inhibitors all raised HDL-C 50-300% but failed to improve outcomes. Torcetrapib increased mortality despite raising HDL by 72%
- **HDL subfraction analysis**: HDL exists as HDL2 (large/buoyant, more protective) and HDL3 (small/dense). Clinical significance still debated

**Bottom line**: even when HDL temporarily ran as high as 2.53 mmol/L, that told us cholesterol cargo but nothing about particle function. With HDL now back at 1.99 mmol/L, the urgency around specialized HDL-function workup is lower unless the higher pattern returns.

## HDL + Low Triglycerides Profile

Current picture is HDL 1.99 mmol/L with triglycerides 1.29 mmol/L — still metabolically good, just less extreme than the Dec 2025 profile.

**What the literature says:**
- High HDL + low triglycerides is generally the most favorable lipid phenotype
- Reflects excellent insulin sensitivity, good metabolic health, efficient reverse cholesterol transport
- HDL/TG ratio is one of the most predictive lipid ratios for cardiovascular risk
- Low triglycerides independently protective - 2021-2025 meta-analysis supports an association between low fasting TG and reduced CV risk independent of other factors
- The paradox: Even this favorable profile may not fully protect against increased risk at extreme upper HDL end

**Assessment**: the combination still reflects good underlying metabolic health and insulin sensitivity. The April 2026 result weakens the case that Dag has a persistently extreme-HDL phenotype needing special explanation.

## HDL and Lp(a) Interaction

Key mechanisms:

1. **No offsetting effect**: Lp(a) promotes atherosclerosis through prothrombotic and oxidized phospholipid mechanisms that HDL's reverse cholesterol transport does not counteract
2. **Independent risk factors**: HDL-C and Lp(a) operate through different pathways. Lp(a) is pro-atherogenic and pro-thrombotic regardless of HDL-C level
3. **Oxidized phospholipids (OxPL)**: Lp(a) is primary carrier of OxPL in plasma. HDL's anti-inflammatory function should neutralize OxPL, but at extreme Lp(a) levels, burden may overwhelm HDL's antioxidant capacity
4. **Non-HDL to HDL ratio**: Study (PMID 41618471, Eur J Med Res, Jan 2026) noted that at very high HDL-C levels, the ratio loses predictive value

**Practical implication**: Do not let very high HDL-C provide false reassurance about Lp(a) risk. Lp(a) at 800+ mg/L remains the dominant cardiovascular risk factor regardless of HDL-C level.

## When High HDL Becomes Concerning

**Genetic causes:**
- SCARB1 mutations: Loss-of-function prevents hepatic cholesterol uptake from HDL, causing very high HDL-C. SCARB1 mutation carriers with high HDL-C have increased CV risk
- CETP deficiency: Heterozygous loss generally protective, homozygous can be neutral or harmful
- ABCA1 mutations: Partial loss-of-function can cause paradoxically high HDL

**Secondary/acquired causes:**
- Primary biliary cholangitis: Can cause very high HDL-C (Lp-X particles, not functional)
- Estrogen therapy/oral contraceptives: Raise HDL-C 10-15%
- Excessive alcohol consumption: Can elevate HDL-C
- Thyroid dysfunction: Can alter lipoprotein metabolism
- Certain medications: Fibrates, ezetimibe, some antiepileptics
- Chronic inflammatory conditions: Can alter HDL composition and quantity

**When to be concerned:**
- HDL-C > 2.6 mmol/L (> 100 mg/dL): Multiple studies support a higher-mortality association
- HDL-C rising progressively: Trend from 2.0 to 2.53 warrants attention
- High HDL-C with other signs of CV disease: If CAC score elevated despite "favorable" lipids
- High HDL-C with elevated inflammatory markers (CRP, IL-6): Suggests HDL may be pro-inflammatory

**For this profile now:**
- The previous high of 2.53 mmol/L is worth remembering, but the newest HDL of 1.99 mmol/L is not in the same caution zone
- Low triglycerides and well-controlled LDL/ApoB still suggest efficient lipid metabolism rather than obvious pathology
- Main concern remains the same: even nice-looking HDL should not provide false reassurance given Lp(a) of 800+
- Consider HDL particle testing only if HDL climbs back into the >2.3-2.6 range repeatedly, not because of one past peak alone

## Key Takeaways for This Profile

1. The old concern was driven by a temporary HDL peak of 2.53 mmol/L, but the newest HDL is 1.99 mmol/L
2. That makes persistent "extreme HDL" less likely and downgrades the urgency of this topic
3. Low triglycerides + well-controlled LDL/ApoB + excellent HbA1c still suggest a broadly favorable metabolic pattern
4. HDL function matters more than quantity — a nice HDL number does not guarantee protection
5. High HDL does NOT offset Lp(a) risk — these factors operate independently
6. Revisit deeper HDL workup only if HDL repeatedly climbs back into the >2.3-2.6 mmol/L range

## Research Trace / Source Anchors

- Preserved threshold summary: optimal HDL-C for cardiovascular mortality is roughly 1.3-2.1 mmol/L; repeated values above ~2.3 mmol/L justify attention, and values above ~2.6 mmol/L are the clearer caution zone.
- The April 2026 HDL of 1.99 mmol/L sits below the caution threshold, so the topic stays monitoring-only unless the higher pattern returns.
- PMIDs: 41618310, 41284745, 40443511, 35583863, 40858201, 41618471


```


---

## Original `antithrombotic-strategy.md`

```markdown
---
topic: Antithrombotic Strategy / High Bleeding Risk
tags: [cardiovascular, antithrombotics, lp(a), gi-bleeding, aspirin, primary-prevention]
priority: important
last_updated: 2026-05-03
confidence: medium-high
abstract: >-
  Very high Lp(a) makes aspirin tempting, but this is still high-risk primary prevention with
  diverticular hemorrhage history and unresolved stool-blood positivity. Default: no aspirin/
  antiplatelet unless documented coronary/vascular disease creates a clinician-led indication.
---

# Antithrombotic Strategy / High Bleeding Risk

## Summary

**No aspirin for current primary prevention.** Lp(a) 838.6 mg/L is a real ASCVD/thrombotic risk enhancer, but aspirin benefit in high-Lp(a) people is still subgroup/observational evidence. The bleeding signal here is not theoretical: prior diverticular hemorrhage plus April 2026 FOB positive and stool RBC present.

## Net-benefit rule

| Situation | Stance |
|---|---|
| No documented ASCVD / no imaging yet | No aspirin; this fails the guideline requirement for low bleeding risk. |
| CAC = 0 | Still no aspirin; lower near-term calcified-plaque risk is not an antiplatelet indication. |
| CAC >0 or non-obstructive CCTA plaque | Intensify lipid/BP first. Aspirin remains unattractive while stool-blood risk is live. |
| Obstructive CAD, MI, stroke/TIA, stent, PAD, or clinician-defined chronic coronary disease | Cardiology + GI decision, not self-directed. Weigh ischemic indication against bleeding/iron trend and colonoscopy quality. |
| Recurrent visible bleed, melena, falling Hb/MCV, ferritin/TSAT drift, or persistent FOB/RBC | Avoid adding antiplatelet burden unless an acute cardiovascular indication overrides. |

## Evidence / context

High-Lp(a) aspirin signal: Women’s Health Study rs3798220-C carriers had lower events on aspirin (HR 0.44; PMID: 18775538). ASPREE genotype analysis found larger MACE reduction in high-LPA genetic subgroups without significant subgroup bleeding increase, but in older European-ancestry secondary analysis (PMID: 36175048). MESA found lower CHD events with aspirin when measured Lp(a) was >50 mg/dL (HR 0.54), but observational (PMID: 38293935). A 2024 systematic review found possible benefit but insufficient bleeding data (PMID: 39191359).

General primary-prevention aspirin: broad RCT meta-analysis shows small cardiovascular benefit but increased major bleeding, NNT 265 vs NNH 210 (PMID: 30667501). USPSTF 2022 applies only to people **not** at increased bleeding risk and calls benefit small at age 40-59 (PMID: 35471505). ACC/AHA 2019 says aspirin may be considered only for selected high-risk adults 40-70 without increased bleeding risk and should not be used for primary prevention at any age when bleeding risk is increased (PMID: 30879355).

GI cost: lower-GI/diverticular guidance supports avoiding non-aspirin NSAIDs after diverticular bleeding and continuing aspirin mainly with established cardiovascular event history. A large cohort found platelet aggregation inhibitors associated with recurrent diverticular hemorrhage (HR 1.47; PMCID: PMC6219900). Translation: avoid casual antithrombotics, but do not stop truly indicated secondary-prevention therapy without clinicians.

## Action

1. Keep aspirin/antiplatelets off the self-directed prevention list.
2. After the experiment window, pair repeat FOB/direct exam with CBC, ferritin, iron/TIBC or TSAT.
3. Use CAC/CCTA/echo to define disease burden; imaging changes lipid/BP intensity before antiplatelet logic.
4. If a clinician proposes aspirin, disclose diverticular bleed + positive FOB/RBC and ferritin/TSAT context.

Research trace: 2026-05-03 **REPLACE/SOFTEN** refresh using PubMed, ACC/AHA, USPSTF, ACC expert review, and lower-GI guidance. Next review: randomized high-Lp(a) aspirin trial, documented ASCVD/plaque, or resolved/persistent GI bleeding branch.

```